An economic model to value companion diagnostics in non-small-cell lung cancer

Author： Lieberthal Robert D   Dudash Kellie   Axelrod Rita   Goldfarb Neil I  

Publisher： Future Medicine

ISSN： 1741-0541

Source： Personalized Medicine, Vol.10, Iss.2, 2013-03, pp. : 139-147

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Economic impact of gefitinib for refractory non-small-cell lung cancer: a Markov model-based analysis

By Chouaid Christos   Monnet Isabelle   Robinet Gilles   Perol Maurice   Fournel Pierre   Vergnenegre Alain  

Current Medical Research and Opinion, Vol. 23, Iss. 7, 2007-07 ,pp. : 1509-1515

Informa Healthcare

Access to resources Recommend Favorite

Molecular Pathology of Non-Small-Cell Lung Cancer

By  

Respiration, Vol. 72, Iss. 3, 2005-06 ,pp. : 313-330

Karger

Access to resources Recommend Favorite

Hycamtin in the Therapy of Non-Small-Cell Lung Cancer

By  

Oncology Research and Treatment, Vol. 21, Iss. 4, 1999-01 ,pp. : 18-21

Karger

Access to resources Recommend Favorite

Prognostic Value of Synaptophysin and Chromogranin A Expression in Patients Receiving Palliative Chemotherapy for Advanced Non-Small-Cell Lung Cancer

By  

Respiration, Vol. 85, Iss. 4, 2012-04 ,pp. : 289-296

Karger

Access to resources Recommend Favorite

Current Standards of Care in Small-Cell and Non-Small-Cell Lung Cancer

By  

Oncology, Vol. 61, Iss. 1, 2001-09 ,pp. : 3-13

Karger

Access to resources Recommend Favorite